首页> 外文OA文献 >Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia

【2h】

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia

机译：Ruxolitinib是一种有效的JaK1 / JaK2抑制剂，可诱导慢性中性粒细胞白血病并发CsF3R突变的等位基因负荷暂时减少

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Gunawan, Arief S.; Mclornan, Donal P.; Wilkins, Bridget; Waghorn, Katherine; Hoade, Yvette; Cross, Nicholas; Harrison, Claire N.;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
专利

1. Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report [J] . Altangerel Otgonbat, Cao Shannan, Meng Juanxia, Oncology letters . 2015 ,第3期

机译：慢性嗜中性粒细胞白血病伴EVI-1过表达，并发CSF3R和SETBP1突变：一例
2. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib [J] . Ammatuna Emanuele, Eefting Matthias, van Lom Kirsten, Annals of hematology . 2015 ,第5期

机译：非典型慢性粒细胞白血病，伴有对JAK抑制剂鲁索替尼无反应的CSF3R T618I和SETBP1突变
3. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib (vol 94, pg 879, 2015) [J] . Ammatuna Emanuele, Eefting Matthias, van Lom Kirsten, Annals of hematology . 2015 ,第6期

机译：非典型慢性粒细胞白血病，伴有对JAK抑制剂鲁索替尼无反应的CSF3R T618I和SETBP1突变（第94卷，第879页，2015年）
4. Detection of de novo IGHV mutations by ultra-deep sequencing from in vitro activated B-cell chronic lymphocytic leukemia cells: Evidence for activation-induced deaminase function [C] . Chu C.C., Patten P.E.M., MacCarthy T, International Congress of Immunology. . 2014

机译：通过来自体外活化B细胞慢性淋巴细胞白血病细胞超深序的De Novo IghV突变检测：活化诱导的脱氨酶功能的证据
5. Ruxolitinib a potent JAK1/JAK2 inhibitor induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia [O] . Arief S. Gunawan, Donal P. McLornan, Bridget Wilkins, 2017

机译：Ruxolitinib是一种强力的JAK1 / JAK2抑制剂可诱导慢性中性粒细胞白血病同时CSF3R突变的等位基因负荷暂时减少
6. Erratum to: Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib [O] . Emanuele Ammatuna, Matthias Eefting, Kirsten van Lom, 2015

机译：错误至：非典型慢性骨髓白血病，伴随着CSF3R T618i和SetBP1突变对Jak抑制剂Ruxolitinib无响应

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia

著录项

相似文献

相关主题

期刊订阅